Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT01415934
Previous Study | Return to List | Next Study

Statin Discontinuation in Advanced Illness

This study has been completed.
National Institute of Nursing Research (NINR)
Information provided by (Responsible Party):
Amy Abernethy, MD, Palliative Care Research Cooperative Group Identifier:
First received: May 10, 2011
Last updated: November 19, 2014
Last verified: November 2014
The purpose of this study is to determine if there is a difference in survival rate at 60 days after enrollment between patients with advanced life-limiting illness for whom statins are discontinued vs. for patients with advanced life-limiting illness who are maintained on the medication. Secondary outcomes of this study will determine the effects of medication cessation on overall survival, important cardiovascular events, quality of life (QOL), symptoms, performance status, polypharmacy issues, satisfaction with care, and costs.

Condition Intervention
Palliative Medicine
Cardiovascular Disease
Other: discontinue statins

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Multisite Randomized Controlled Trial of Continuing vs. Discontinuing Statins

Resource links provided by NLM:

Further study details as provided by Palliative Care Research Cooperative Group:

Primary Outcome Measures:
  • Survival Time [ Time Frame: 60 days minimum ]
    To determine, among patients with life-limiting illness, if there is a difference in the proportion who die within 60 days after enrollment between patients for whom statins are discontinued vs. patients who are maintained on the medication.

Enrollment: 380
Study Start Date: May 2011
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Continue Statins
Participant will continue on statins as per usual
Experimental: Discontinue statins
Participant will stop taking their statin drugs
Other: discontinue statins
patients will be randomized to either continue taking statins or discontinue.

Detailed Description:

Currently, over 80% of the population is expected to die of chronic life-limiting illnesses, predominant among which are the various manifestations of cardiovascular disease, cancer, dementia, and chronic lung disease. Patients with high cholesterol and those potentially at risk for atherosclerotic heart disease and stroke are often treated preventively with HMG Co-A reductase inhibitors (a.k.a., statins). Clinical trial evidence supports the use of statins for patients with hyperlipidemia and established ischemic heart disease to reduce risk of future cardiovascular events and mortality, and to reduce risk of future cardiovascular events in patients with multiple cardiac risk factors. Beneficial outcomes are evident in these trials after 3-6 years of treatment. Hence, statins are among the most prescribed medications in the world. In the United States, over 25% of Medicare beneficiaries take a statin medication. Statin medications are frequently continued until the patient can no longer eat or swallow at the end of life, because there are no evidence-based guidelines regarding when or how to discontinue medications for co-morbidities. The risks and costs vs. benefits of statins for palliative care patients, for whom prognosis is limited, remains a genuine clinical uncertainty. Meanwhile, medications for symptoms and other concerns accumulate as illness progresses, and therefore polypharmacy and compounding medication side effects are troublesome problems in the setting of advanced life-limiting illness. While multiple studies have demonstrated the benefit of long-term preventive statin use for patients at cardiovascular risk, other studies have supported the discontinuation of medications (specifically statins) in end-stage disease. A rational approach to medication discontinuation, specifically statin discontinuation, therefore has the potential to reduce patient burden, polypharmacy, and side effects, while also preserving healthcare resources for more beneficial interventions.

This study a multi-site randomized controlled trial of discontinuing vs. continuing statin medications in patients with advanced life-limiting illness. Eligible participants are adults with advanced life-limiting illness with an estimated prognosis of 1-6 months who are on statins for primary or secondary prevention of cardiovascular events. The primary outcome is survival rate at 60 days; secondary outcomes address cardiovascular events, polypharmacy, medication adverse effects, quality of life (QOL), and measures of the patient's health-related experience. The primary hypothesis is that discontinuing statins will not influence survival. Secondary hypotheses are that discontinuation of statins will not adversely affect cardiovascular events or overall QOL, but will improve statin-related symptoms and decrease polypharmacy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age >18 years old;
  • have an advanced life-limiting illness;
  • have a life expectancy of >1 month, AND patient exhibits declining functional status, defined as a reduction in Australia-modified Karnofsky Performance Status (AKPS)22 score to <80% in the previous 3 months;
  • be on a statin medication for primary or secondary prevention of cardiovascular disease for ≥3 months;
  • have adequately intact cognitive status to provide informed consent and complete the baseline assessment, as evidenced by a Short Portable Mental Status Questionnaire (SPMSQ)23 score of ≥6;
  • provide informed consent; and,
  • speak and read English at or above a grade 5 level (per patient or caregiver report).

Exclusion Criteria:

  • primary treating physician/care provider estimates their life expectancy as < 1 month;
  • under the care of a primary treating physician/primary care provider who is unwilling to have the patient enrolled;
  • not consenting;
  • having known active cardiovascular disease or sufficient risk of active cardiovascular disease to require ongoing therapy with statin drugs, in the opinion of the treating physician; OR,
  • exhibiting obvious symptoms of myositis, known liver function test (LFT) abnormalities of >2.5x the upper limit of normal (ULN), known creatine kinase (CK) abnormalities of >2.5x ULN, or other contraindications to continuing statins, in the opinion of the treating physician.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01415934

United States, Alabama
University of Alabama, Birmingham
Birmingham, Alabama, United States, 35294
United States, California
San Diego Hospice and the Institute for Palliative Medicine
San Diego, California, United States, 92103
United States, Colorado
University of Colorado, Denver
Denver, Colorado, United States, 80217
Kaiser Permanente
Denver, Colorado, United States, 80231
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
United States, Missouri
Washington University
St Louis, Missouri, United States, 63110
United States, New York
Beth Israel Medical Center
New York, New York, United States, 10003
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, North Carolina
University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Duke University Medical Center
Durham, North Carolina, United States, 27710
Four Seasons Hospice and Palliative Care
Flat Rock, North Carolina, United States, 28731
United States, Ohio
Western Reserve
Cleveland, Ohio, United States, 44106
United States, Virginia
Capital Caring
Falls Church, Virginia, United States, 22042
United States, Wisconsin
University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States, 53792
Sponsors and Collaborators
Palliative Care Research Cooperative Group
National Institute of Nursing Research (NINR)
Principal Investigator: Amy Abernethy, MD Duke University
Principal Investigator: Jean Kutner, MD University of Colorado, Denver
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Amy Abernethy, MD, Palliative Care Research Cooperative Group Identifier: NCT01415934     History of Changes
Other Study ID Numbers: PCRC-001.1
UC4NR012584 ( US NIH Grant/Contract Award Number )
Study First Received: May 10, 2011
Last Updated: November 19, 2014

Additional relevant MeSH terms:
Cardiovascular Diseases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Lipid Regulating Agents processed this record on April 26, 2017